Evaluation of [18F] FNM biodistribution and dosimetry based on whole-body PET imaging of rats

 

Guardado en:
Detalles Bibliográficos
Autores: Salabert, Anne Sophie, Mora Ramírez, Erick, Beaurain, Marie, Alonso, Mathieu, Fontan, Charlotte, Tahar, Hafid Belhadj, Boizeau, Marie Laure, Tafani, Mathieu, Bardiès, Manuel, Payoux, Pierre
Formato: artículo original
Fecha de Publicación:2018
Descripción:Introduction: The aim of this work was to study the biodistribution, metabolism and radiation dosimetry of rats injected with [18F]FNM using PET/CT images. This novel radiotracer targeting NMDA receptor has potential for investigation for neurological and psychiatric diseases. Methods: Free fraction and stability in fresh human plasma were determined in vitro. PET/CT was performed on anesthetized rats. Organs were identified and 3D volumes of interest (VOIs) were manually drawn on the CT in the center of each organ. Time activity curves (TACs) were created with these VOIs, enabling the calculation of residence times. To confirm these values, ex vivo measurements of organs were performed. Plasma and urine were also collected to study in vivo metabolism. Data was extrapolated to humans, effective doses were estimat ed using ICRP-60 and ICRP-89 dosimetric models and absorbed doses were estimated using OLINDA/EXM V1.0 and OLINDA/EXM V2.0 (which use weighting factors from ICRP-103 to do the calculations). Results: The [18F]FNM was stable in human plasma and the diffusible free fraction was 53%. As with memantine, this tracer is poorly metabolized in vivo. Ex vivo distributions validated PET/CT data as well as demonstrating a decrease of radiotracer uptake in the brain due to anesthesia. Total effective dose was around 6.11 μSv/MBq and 4.65 μSv/MBq for female and male human dosimetric models, respectively. Conclusions: This study shows that the presented compound exhibits stability in plasma and plasma protein bind ing very similar to memantine. Its dosimetry shows that it is suitable for use in humans due to a low total effective dose compared to other PET radiotracers.
País:Kérwá
Institución:Universidad de Costa Rica
Repositorio:Kérwá
Lenguaje:Inglés
OAI Identifier:oai:kerwa.ucr.ac.cr:10669/88084
Acceso en línea:https://www.sciencedirect.com/science/article/pii/S0969805117303633?via%3Dihub
https://hdl.handle.net/10669/88084
Palabra clave:Dosimetry
[18F] FNM
Position emission tomography (PET)
NMDA receptor
OLINDA
RADIACIÓN
CANCER